Challenging Conventional Transferrin Receptor Design Paradigms with Enhanced Brain Delivery™ Bispecific Antibodies

• Demonstrate efficient TfR-mediated transcytosis using a high-affinity, bivalent antibody architecture that achieves robust CNS exposure despite prevailing assumptions in the field
• Present translational mouse and non-human primate data showing substantially enhanced brain penetration while preserving selective binding to pathogenic amyloid beta oligomers
• Explore a differentiated TfR binding epitope that avoids hematological liabilities (anemia) associated with earlier BBB shuttle approaches
• Share drug candidate selection, lead characterization and dose-ranging studies in rodent and non-human primates of Enhanced Brain Delivery™ therapeutics for Alzheimer’s disease

Speakers:

Paul Shughrue

Vice President, Program Leader & Head of Research

Acumen